Endoscopic sleeve gastroplasty for metabolic dysfunction-associated steatotic liver disease

被引:0
|
作者
Matteo, Maria Valeria [1 ,2 ]
Gualtieri, Loredana [3 ]
Bove, Vincenzo [1 ,2 ]
Palumbo, Giulia [1 ,2 ]
Pontecorvi, Valerio [1 ,2 ]
De Siena, Martina [1 ,2 ]
Barbaro, Federico [1 ,2 ]
Spada, Cristiano [1 ,2 ]
Boskoski, Ivo [1 ,2 ]
机构
[1] Fdn Policlin Univ Agostino Gemelli IRCCS, Digest Endoscopy Unit, Largo A Gemelli 8, I-00168 Rome, Italy
[2] Univ Cattolica Sacro Cuore, Rome, Italy
[3] Sapienza Univ Rome, Dept Surg, Rome, Italy
关键词
Bariatric endoscopy; endoscopic sleeve gastroplasty; ESG; MASLD; NAFLD; MASH; NASH; obesity; BODY-MASS INDEX; WEIGHT-LOSS; NONALCOHOLIC STEATOHEPATITIS; BARIATRIC SURGERY; CONTROLLED-TRIAL; GASTRECTOMY; RISK; EFFICACY; OBESITY; COMORBIDITIES;
D O I
10.1080/17474124.2024.2387231
中图分类号
R57 [消化系及腹部疾病];
学科分类号
摘要
Introduction: Metabolic dysfunction-associated steatotic liver disease (MASLD, formerly nonalcoholic fatty liver disease - NAFLD) is a chronic liver condition linked to obesity and metabolic syndrome. It affects one-third of people globally and, in some cases, can lead to metabolic dysfunction-associated steatohepatitis (MASH, formerly nonalcoholic steatohepatitis, NASH) and fibrosis. Weight loss is crucial for the treatment of MASLD, but diet and lifestyle modifications often fail. Areas covered: In recent years, endoscopic sleeve gastroplasty (ESG) has gained popularity as an effective and minimally invasive option for obesity treatment, with widespread use worldwide. We present a current overview of the most significant studies conducted on ESG for the management of obesity and MASLD. Our report includes data from published studies that have evaluated the impact of ESG on noninvasive hepatic parameters used to estimate steatosis and fibrosis. However, at present, there are no data available on liver histology. Expert opinion: ESG has shown promising results in treating MASLD evaluated by noninvasive tests, but current data is limited to small, nonrandomized studies. More research is needed, particularly on the effects of ESG on histologically proven MASH. If future research confirms its efficacy, ESG may be incorporated into treatment guidelines in the future.
引用
收藏
页码:397 / 405
页数:9
相关论文
共 50 条
  • [1] THE ROLE OF REVISIONAL ENDOSCOPIC SLEEVE GASTROPLASTY (RESG) TO TREAT METABOLIC DYSFUNCTION-ASSOCIATED STEATOTIC LIVER DISEASE (MASLD)
    Hedjoudje, Abdellah
    Hoff, Anna C.
    Nunes, Gabriel C.
    Barrichello, Sergio
    Huang, Yuting
    Patel, Tushar
    Kumbhari, Vivek
    Badurdeen, Dilhana S.
    GASTROENTEROLOGY, 2024, 166 (05) : S1638 - S1639
  • [2] Metabolic Dysfunction-Associated Steatotic Liver Disease
    Ali, Sajjadh M. J.
    Lai, Michelle
    ANNALS OF INTERNAL MEDICINE, 2025, 178 (01) : ITC1 - ITC17
  • [3] Metabolic dysfunction-associated steatotic liver disease and the heart
    Driessen, Stan
    Francque, Sven M.
    Anker, Stefan D.
    Cabezas, Manuel Castro
    Grobbee, Diederick E.
    Tushuizen, Maarten E.
    Holleboom, Adriaan G.
    HEPATOLOGY, 2023,
  • [4] Retinopathy in Metabolic Dysfunction-Associated Steatotic Liver Disease
    Orfanidou, Myrsini
    Polyzos, Stergios A.
    MEDICINA-LITHUANIA, 2025, 61 (01):
  • [5] Metabolic dysfunction-associated steatotic liver disease and atherosclerosis
    Castillo-Nunez, Yulino
    Almeda-Valdes, Paloma
    Gonzalez-Galvez, Guillermo
    Arechavaleta-Granell, Maria del Rosario
    CURRENT DIABETES REPORTS, 2024, 24 (07) : 158 - 166
  • [6] Metabolic dysfunction-associated steatotic liver disease in adults
    Huang, Daniel Q.
    Wong, Vincent W. S.
    Rinella, Mary E.
    Boursier, Jerome
    Lazarus, Jeffrey V.
    Yki-Jarvinen, Hannele
    Loomba, Rohit
    NATURE REVIEWS DISEASE PRIMERS, 2025, 11 (01):
  • [7] Diabetes and Metabolic Dysfunction-Associated Steatotic Liver Disease
    Stefan, Norbert
    Roden, Michael
    DIABETOLOGIE UND STOFFWECHSEL, 2024, 19 : S290 - S296
  • [8] Metabolic dysfunction-associated steatotic liver disease in children
    Goyal, Nidhi P.
    Xanthakos, Stavra
    Schwimmer, Jeffrey B.
    GUT, 2025,
  • [9] Menopause and metabolic dysfunction-associated steatotic liver disease
    Polyzos, Stergios A.
    Goulis, Dimitrios G.
    MATURITAS, 2024, 186
  • [10] Nutrients associated with metabolic dysfunction-associated steatotic liver disease
    Jeong, Seogsong
    JOURNAL OF HEPATOLOGY, 2024, 80 (02) : e81 - e82